(10) and D-[5,6-3H2]6-deoxyglucose (ll) were incorporated into neomycins B and C using a growing culture of Streptomyces fradiae. D-[6-3H]6-Deoxy-5-ketoglucose was incorporated into neomycin, as efficiently as the well established precursor D-glucose, and wasfound to label exclusively the 2-deoxystreptamine ring of the antibiotic. The results strengthened the previous proposals that in the formation of 2-deoxystreptamine the C-6 hydroxyl group of D-glucose is removed prior to the cyclisation reaction. Studies using the incorporation of d-[3-3H]glucose, D-[3,4-3H2]glucose and D-[5-3H]glucose into neomycin followed by the degradation of the latter established that in the biosynthesis of the 2-deoxystreptamine ring the C-4 and C-5 hydrogen atoms of glucose are removed. The loss of the C-4 hydrogen atom of the glucose is attributed to the formation of a 4-keto derivative which facilitates the removal of the C-5 hydrogen atom thus setting the stage for the expulsion of the C-6 hydroxyl group. The 5,6-olefinic intermediate formed in the process then undergoes cyclisation eventually releasing 2-deoxyinosose. The enzyme systems which participate in the conversion of D-glucose equivalent into 2-deoxyinosose may be described as 2-deoxyinosose synthase that in broad mechanistic terms resembles dehydroquinate synthase.
A large group of clinically useful antibiotics, to which streptomycin and neomycin belong, are classified as aminoglycoside-aminocyclitol antibiotics. The name highlights the fact that these antibiotics, in addition to an array of variously modified amino-sugars, contain an unusual cyclohexane derivative which can either be hexa-substituted as the streptamine unit (1) of streptomycin or penta-substituted as the 2-deoxystreptamine ring (2) . The latter unit is present in neomycin (3) and more than fifty other related antibiotics. It is now knownthat the carbon skeletons of both types of aminocyclitols (1 and 2) arise from D-glucose1>2) and the elegant studies of Walker and Walker3) have established that, in the formation of the streptamine ring system of streptomycin, the key event is the inositol synthase catalysed cyclisation of glucose 6-phosphate into inositol 1-phosphate, Scheme 2. The latter, through a multistage process, is then converted into streptidine (this is a diguanidinated derivative of 1). The knowledge of the latter biosynthesis provided the stimulus to consider the possibility that a cyclisation process similar to that shown in Scheme 2, followed by the reductive removal of the unwanted hydroxyl group, may also be involved in the formation of 2-deoxystreptamine. Gradually however observations were made which questioned this hypothesis and suggested that the two aminocyclitols (1 and 2) may be synthesised by two entirely different mechanisms. For example, the patterns for the incorporation of the C-skeleton ofD-glucose f Present address: PHLS, Centre for Applied Microbiology and Research, Porton Down, Salisbury, Wiltshire, England. into the two aminocyclitols were found to be different, the C-6 of glucose occupied position 2 in deoxystreptamine4) but position 6 in the streptamine ring5 '6) . Furthermore, the studies of Kakinumaet al. on ribostamycin7) and our work on neomycin8) revealed that the 2-deoxystreptamine ring of these antibiotics was formed from D-glucose with the retention of both of its C-6 hydrogen atoms. Since the mechanism of the type shown in Scheme2 requires the loss of one of the C-6 hydrogen atoms of glucose9)
during the condensation reaction, the results7'8* suggested that the pathways for streptamine and 2-deoxystreptamine biosynthesis diverged prior to the cyclisation stage and led to the proposal of two closely related mechanisms7'8) (Paths a and b, Scheme 3) for the construction of the deoxy centre of the aminocyclitol (2). The commonfeature in both the mechanisms is the involvement of the enolic intermediate (7, Scheme 3) which participates in nucleophilic attack at the C-l carbonyl producing a deoxycarbocyclic ring. The difference in the two mechanisms, however, is that whereas in Path a, Scheme 3, the enolic species is produced via a direct elimination reaction necessitating the removal of a non-activated C-5 hydrogen, this feature is avoided in the alternative mechanism (Path b) where hydrogen removal is facilitated by the generation of a carbonyl function. These features have been studied using two interlocking approaches. Firstly, two deoxy sugars, 6-deoxyglucose (ll) and 6-deoxy-5-ketoglucose (10), labelled with Neomycin C has the aminomethyl group in Ring IV in the equatorial orientation.
The scheme highlights that one of the C-6 hydrogen atoms of glucose 6-phosphate is removed m the condensation process and that the C-6 of glucose occupies position 6 in streptamine (1).
R in 4 is a leaving group presumably a phosphate. The scheme shows the retention of both the C-6 hydrogen atoms of glucose in the predicted cyclised product (8) . The further conversion of 8 into 2 occurs via a multistage process involving transamination at C-3 and oxidation followed by transamination at C-l. The solid arrows show the preferred reaction sequence. That the H^(H#) and HSi ("H) in the precursor (4) occupy axial and equatorial orientations, respectively in the product (2) is shown in refs 7
and13.
3H were synthesised and their role as precursors of neomycin evaluated using Streptomyces fradiae. Secondly, the fate of the C-3, C-4, and C-5 hydrogen atoms of glucose during the incorporation of the latter into the 2-deoxystreptamine ring of the antibiotic was investigated with the aid of appropriately tritiated glucose samples. The paper extends the approaches used previously for the delineation of the mechanisms of the formation of neosamines B and C rings of neomycin10) (these are Ring I and Ring IV, respectively in structure 3) to the biosynthesis of 2-deoxystreptamine and gives a fuller account of studies originally published in a preliminary communication11} and in a Ph. D. Thesis12).
Results and Discussion The fact that the two pro-chiral hydrogen atoms of glucose are stereospecifically7) transferred to C-2 of 2-deoxystreptamine suggests that if an enol of the type (7) To test this hypothesis 6-deoxy-5-ketoglucose containing 3H at C-6 was synthesised according to the sequence of Scheme 4 as described in the Experimental section, and incubated with S. fradiae. Under the conditions used in this study S. fradiae produces two isomers of the antibiotic, neomycins B and C (Scheme 1) in the ratio of9 : 1. Hereafter the mixture is referred to as neomycin and this was found to contain 0.3% of the 3H label originally present in the precursor (Table 1) which by degradation was shown to be located only in the 2-deoxystreptamine ring of neomycin. The conclusion was confirmed and further evaluated by another experiment in which a mixture of [£/-14C]glucose and [6-3H]6-deoxy-5-ketoglucose was fed to S. fradiae and a comprehensive degradation of the doubly labelled neomycin performed. The results are summarised in Table 2 and allow several conclusions to be drawn. The fact that the 3H-14C ratio of neomycin was 1/4 that of the original mixture of two precursors suggests that 6-deoxy-5-keto sugar is incorporated as well in the aminocyclitol ring as incubated with culture of S. fradiae (9 x 10ml) for 96 hours. The antibiotic produced as a mixture of neomycins B and C (in the ratio of 9: 1) was isolated and purified by ion exchange chromatography10). Neosamine C 0.0
The antibiotic biosynthesised from the above precursors as in Table 1 was degraded to furnish the various subunits according to the sequence of Scheme 5.
The mixture was hydrolysed to give the commonneamine unit 12 which was further degraded to 14and15.
is glucose. This is because glucose is known to label the four rings of the antibiotic about equally while 6-deoxy-5-ketoglucose was expected to be incorporated specifically only into the 2-deoxystreptamine ring. In order to shed further light on the labelling pattern the neomycin was hydrolysed first to neamine (Ring I-Ring II) plus neobiosamine (Ring Ill-Ring IV) and neamine then further converted into neosaminol C (14) and 2-deoxystreptamine (2, Scheme 5). The radiochemical data in Table 2 clearly show that 3H was located only in 2-deoxystreptamine and the 3H-14C ratio of the latter was identical to that of the original mixture. From the data, without making any allowance for the loss of tritium accompanying the conversion of the methyl group of 6-deoxy-5-ketoglucose into the methylene carbon of 2-deoxystreptamine, it appears that the two sugars (6-deoxy-5-ketoglucose (10) and glucose) are comparable precursors of the aminocyclitol. For comparison, feeding experiments were also performed with another deoxy sugar, 6-deoxyglucose (ll), and it was found that this precursor was incorporated in an 0.03% radiochemical yield into neomycins. Since in the biosynthesis of 2-deoxystreptamine the 5-3H of [5,6-3H2]6-deoxyglucose will be eliminated weestimate that the latter sugar is 1/5 as efficient a precursor of the aminocyclitol as is its 5-keto counterpart. The relative efficiency of the incorporation suggests but does not prove that 6-deoxyglucose is incorporated into 2-deoxystreptamine via the 5-keto derivative. Irrespective of the validity of this assumption the results described in Tables 1 and 2 strongly suggest that in the biosynthesis of 2-deoxystreptamine the removal of the C-6 substituent of glucose precedes cyclisation. Wenow turn to the feeding experiments with samples of glucose containing 3H at C-3, C-4 and C-5. The extent of 3H retention or loss in the biosynthetic experiments performed with these labelled precursors was quantified using a double labelling approach in which [£/-14C]glucose served as an internal reference.
were fed to growing cultures of S. fradiae and neomycin was isolated, purified and degraded to obtain its four rings. Based on the 14C radioactivity originally used, the incorporations of glucose into the antibiotic in these experiments were about 0.9% (Table 3 ). The incorporation of 3H from [5-3H] glucose into various subunits of neomycin has been reported previously10). In the present context suffice to draw attention to the fact that the ribose ring of neomycin was formed retaining the original C-5 tritium to the extent of 80%which proved that the glucose skeleton was incorporated intact into the antibiotic. The 2-deoxystreptamine ring, however, contained only 10% of the 3H originally present in the precursor glucose. The C-5 of glucose occupies C-3 in 2-deoxystreptamine and since the amino group in this position (C-3) is expected to arise via a carbonyl group, the C-5 tritium will be removed in the attendant reaction. In the experiment in which [t/-14C, 3-3H]-and [£/-14C, 3,4-3H2]glucose samples were used as precursors the 3H-14C atomic ratios of the derived neosaminol (Ring I) and ribitol (Ring III) showed the complete retention of the original 3H. These results provide the important information that under the incubation conditions used in the present study the exogenously added glucose was incorporated into the antibiotic without the labilisation of 3H or the rearrangement of the carbon skeleton. With this information in hand it is justified to assume that the 3H content of 2-deoxystreptamine genuinely reflects the mechanism(s) through which its carbocyclic ring is produced from glucose. Table 4 shows that 3H-14C ratio of 2-deoxystreptamine was half that of glucose when the latter precursor was labelled with 3Hat C-3 as well as C-4 thus suggesting that in the biosynthesis one of the hydrogen atoms of the glucose is removed. On the other hand [£/-14C, 3-3H]-D-glucose was incorporated into 2-deoxystreptamine with complete maintenance of its 3H -14C ratio which proves that it must be the C-4 tritium that is labilised in the synthesis from 3,4-tritiated glucose. That in Samples of doubly labelled hexoses were incubated with cultures of S. fradiae (20 x 10ml) for 12 hours. The antibiotic was isolated and purified in Table 1 . The percentage incorporation in the last column is based on the 14C content of the precursor. A comparison of the 3H -14C and atomic ratios of neomycin subunits with those of the precursor glucose is shown. The details of the incubation are the same as in Table 3 and those of degradation are described in the experimental section and elsewhere7'1°~12).
both cases the tritium remaining in 2-deoxystreptamine was resident at its C-5 (which corresponds to C-3 of glucose) was shown through the isolation of the C-5 as formate that contained all the 3H radioactivity of the ring while the aldehyde (15, Scheme 5) containing the remaining carbon skeleton (C-l, C-2, C-3, C-4 and C-6) of 2-deoxystreptamine was completely devoid of any 3H.
These results unambiguously prove that the formation of the 2-deoxystreptamine ring of neomycin is attended by the loss of the C-4 hydrogen atom of the precursor glucose. This could occur either by the direct oxidation at this, position to produce a 4-keto intermediate or indirectly through oxidation at C-5 followed by a prototropic rearrangement yielding an enediol intermediate which rearranges to the 4-ketospecies (5). The latter contains the electronic arrangement to undergo a facile elimination reaction, 5->6. The stage at which the C-4 carbonyl function of6 is reduced cannot be deduced from the experiments of Table 4 . However, when the results are taken in conjunction with the observation that 6-deoxy-5-ketoglucose is a good precursor of 2-deoxystreptamine then an argument may be developed that the C-4 carbonyl group of the intermediate of the type 6 is reduced prior to cyclisation, thus favouring the sequence 6->7->8->2 rather than 6->9->8-+2. The rationale underpinning the conclusion is that the sequence 6->7->8->2 when extended to the non-physiological conversion of 6-deoxy-5-ketoglucose into 2-deoxystreptamine requires only one additional reaction, (i.e. the enolization of 10->7), that is not involved in the physiological pathway. However, much greater catalytic versatility is required to explain the cyclisation of 6-deoxy-5-ketoglucose if the normal pathway from glucose followed the sequence 6-»9->8-»2. Furthermore, the reduction of the C-4 carbonyl group prior to cyclisation will have the added advantage of making the C-6 of the enol (7) electron rich enabling this position to add to the C-l carbonyl group. On the other hand the C-6 position in the enedione (6) due to the electron withdrawing property of the C-4 carbonyl group will be deactivated for such a condensation reaction. The electronic considerations thus make the sequence 6->T->8->2 preferable over the alternative 6^9->8->2, also see ref 13. Several biological transformations ofmonosaccharides which are attended by an internal redox reaction are known. The examples of these are the formation of deoxy and epimeric sugars14~16) In general, the enzymes catalysing these transformations contain a tightly bound nucleotide co factor NADor NADP, which participates in the oxidation of the C-4 hydroxyl group of the hexose. At a latter stage in the Another experimental finding which needs to be explained is that the two C-6 pro-chiral hydrogen atoms of glucose are incorporated stereospecifically7 '13) into 2-deoxystreptamine and these, HRe and Hs/, occupy the axial and equatorial orientations, respectively at C-2 of the aminocyclitol ring as shown in Scheme4. It is attractive to assume that the stereochemistry of the two hydrogen atoms when these become the part of an unstable enolic system is maintained by fixing the geometry of the double bond through the formation ofa pyronose ring (6a and 7a) which is opened only at thejuncture of the cyclisation reaction.
In the light of these cumulative considerations we predict that the immediate product of cyclisation of D-glucose is 2-deoxyinosose and thus the enzyme involved in the process may be designated a 2-deoxyinosose synthase. The intermediacy of 2-deoxy-scy//oinosose and its aminated counterpart in the biosynthesis of 2-deoxystreptamine has been demonstrated previously17~20). It is interesting to draw attention to the fact that the mechanismconsidered in this paper for the formation of the carbocyclic ring of 2-deoxystreptamine is reminiscent of the reaction catalysed by dehydroquinate synthase21}.
Materials and Methods
The laboratory chemicals were ex-stock from BDH or Kochlight. iodide (10g, 600mmol) were dissolved in dry acetone (80ml). The solution was refluxed for 2hours whereupona white precipitate of methyl sodium sulfonate was formed. The solution was filtered, and the residue washed several times with acetone. The filtrate was evaporated under reduced pressure to a residue which was dissolved in chloroform and washed with water. The chloroform solution was evaporated under reduced pressure, the crude material was crystallised from methanol to give the title compound(7 g, 60%). lH NMR (60MHz, DMSO-</6) d 1.9 (3H, s, CH3), 2.0 (3H, s, CH3), 2.1 (3H, s, CH3), 3:0
The preceding compound was converted to methyl pyranoside 5,6-a-glucosene as described elsewhere23*. The latter (170mg) was dissolved in a solution (l ml) prepared from trifluoroacetic acid (0.8ml) and tritiated water (0.2ml, ICi of 3H). The reaction mixture was left for about one hour at room temperature. The solvents were removed under reduced pressure, the residue was then dissolved in water followed by evaporation in vacuo. The preceding operation was repeated 5 times. TLCof the residue showed the presence of three bands, the desired compound being the major product (Rf 0.3, 70%). For purification 9mg of the crude residue containing 1.9x l08dpm of 3H was spotted on a 10cm x 20cm TLCplate which was developed in an ascending tank with chloroform -methanol (4 : 1, v/v). The plate was dried and scanned for radioactivity. After detection the product was eluted with methanol and the solution evaporated to yield D- [6- PtO2 (20mg) was suspended in ethyl acetate (20ml) and shaken in an atmosphere of tritium gas generated by the reaction (23H2O+2Li->2Li(OH)+3H2) at room temperature. Methyl pyranoside of 2,3,4-tri-O-acetyl, 5,6-a-glucosene23) (50mg in l ml of ethyl acetate) was then added, and the suspension shaken with tritium until the absorption of the gas ceased. Thetime required for the reduction wasabout 2 hours. Removalof the catalyst and concentration under pressure afforded a mixture which was resolved by TLC into two isomers, the glucose derivative 15% (Rf 0.7) and the idose derivative 85% (Rf 0.73).
The preceding mixture (4mg, 2.5 x 108 dpm), was deacylated23) and spotted on a 10cm x 20cm TLC plate which was developed in an ascending tank with chloroform -methanol (4 : 1, v/v). The plate was dried and was scanned for radioactivity. The glucose derivative, which was identified by co-migration with an authentic sample, was eluted with methanol and the material was subjected to two further rounds of chromatographyto obtain a homogeneous sample.
A solution of the preceding compound, methyl D-6-deoxy-glucopyranoside (1.6mg, 90 x 106 dpm), in 1 m hydrochloric acid (10ml) was heated under reflux for 4hours. The cooled solution was evaporated under reduced pressure. Analytical TLCdeveloped in chloroform -methanol (4 : 1, v/v) showed one spot (Rf 0.3) corresponding to the position of authentic 6-deoxy-a-D-glucose.
The Incorporation of Labelled Precursors into Neomycins B and C Streptomyces fradiae (ATCC 10745) spores were produced on Bacto-inorganic salt agar, transferred to a Tryptic soya broth medium (10 ml, prepared according to manufacturer's instructions) and incubated for 40hours at 28°C. The fully grown culture (1.0ml) and a 30% (w/v) solution of maltose (0.5ml) were then added to a defined medium10) (9.0ml) contained in a 125-ml conical flask. Several such flasks were normally prepared and incubated together at 28°C on a rotary shaker (1 50 revolutions/minute) for 48 hours until the cell density reached 80-90% of that expected for the stationary phase. The labelled precursors whose amounts and radiochemical characteristics are defined in Tables 1, 2 and 3 in water (2ml) were added to the cultures and the incubation continued for 96hours for the experiments of Tables 1 and 2 , and 12 hours for those in Table 3 . The antibiotic produced under these conditions consists of neomycins B and C in the ratio of 9: 1. In the present study the antibiotic was isolated and purified as a mixture of the two isomers and degraded to neamine, neobiosamine, 2-deoxystreptamine and neosaminol C as described previously10). The further degradation of 2-deoxystreptamine is detailed below.
Degradation of 2-Deoxystreptamine
The labelled 2-deoxystreptamine was mixed with carrier and the resulting material (25 mg) was dissolved in hot methanol (50ml). Dowex 1-X2 resin (carbonate form washed with methanol prior to use, 20ml) was added to the preceding solution and the mixture stirred for 5 minutes (pH 8.0) then benzoyl chloride (0.1 ml) was added dropwise over 10minutes with stirring.
The mixture was kept at room temperature for 45 minutes with occasional stirring and the pH was maintained between 6 and 7 by adding Dowex 1-X2 (CO3") and then filtered. The resin was washed several times with MeOH-H2O (7 : 3, v/v). The filtrate was treated with 10ml of Dowex 50W-X8(H+), stirred for 5 minutes and then filtered. The resin was washed with MeOH-H2O(7 : 3, v/v) five times. The combined solvent mixture was evaporated to dryness using a rotary evaporator. The residue was washedseveral VOL.45 NO. 6 THE JOURNAL OF ANTIBIOTICS 993 times with diethyl ether to remove traces of benzoic acid, and yielded 7V,iV'-dibenzoyl-2-deoxystreptamine as a white powder (25mg). Analysis by TLC (using ethyl acetate-methanol, 4: 6) showed one spot at Rf 0.6; visualised under UVlight.
The preceding iV,./V'-dibenzoyl-2-deoxystreptamine (20 mg) was dissolved in 50 ml ofMeOH -H2O (7 : 3, v/v) with stirring for 20minutes and then treated with a solution of sodium periodate (150mg in 5ml water) which was added dropwise over a 10-minute period. The stirring was continued for another 5 minutes. The reaction (clear solution) was then left in the dark at room temperature without stirring for 24hours. The pH of the solution was adjusted to 10 with sodium hydroxide and the solvent removed using a rotary evaporator. The dialdehyde and its cyclic derivative were extracted with ethyl acetate (5 x 5 ml). The extracts were combinedand the solvent was evaporated to dryness in vacuo to give a white solid residue (16mg). Analysis of the product by TLC using ethyl acetate and detection by UVlight showed the presence of two spots of Rf, 0.55 and 0.4 attributed to 2,4-diamino-Ar,7V/-dibenzoylglutardialdehyde and cyclic structure (the dialdehyde combined with one molecule of water), respectively. The pH of the residue left after ethyl acetate extraction which contained sodium formate was adjusted to 2 by orthophosphoric acid and the solution freeze-dried. The formic acid was collected, the pH adjusted to 7.5 with NaOHand the sample freeze-dried. The resulting sodium formate was analysed for its 3H -14C ratio.
